Breast Cancer Index is a test that can help you and your doctor make a more personalized treatment decision about extending your anti-estrogen therapy. If you are an HR+ breast cancer survivor, Breast Cancer Index (BCI) is a non-invasive test that can provide more information using the original biopsy of your tumor to help you and your physician make a better treatment plan FOR YOU beyond the 5-year mark.

This test provides you and your doctor with information to help decide whether to extend or end anti-estrogen therapy beyond year 5 by analyzing your risk of breast cancer coming back after year 5 (late recurrence) and your likelihood of benefit from extending anti-estrogen therapy for an additional 5 years.

For more information and for intended uses and limitations, please go to: https://www.breastcancerindex.com

Navigating Breast Cancer Index® (BCI™) Results
1:42
Navigating Breast Cancer Index® (BCI™) Results
What Is the Breast Cancer Index® (BCI™) Test?
3:57
What Is the Breast Cancer Index® (BCI™) Test?
Collaborative Decision-Making for Extended Endocrine Therapy in Early-Stage, HR+ Breast Cancer
4:36
Collaborative Decision-Making for Extended Endocrine Therapy in Early-Stage, HR+ Breast Cancer
The Breast Cancer Index® Test Eligibility Criteria
5:07
The Breast Cancer Index® Test Eligibility Criteria
Why Not Extend Endocrine Therapy for All Patients Who Are Tolerating?
2:11
Why Not Extend Endocrine Therapy for All Patients Who Are Tolerating?
Differentiating the Breast Cancer Index® Test from Other Genomic Assays
2:32
Differentiating the Breast Cancer Index® Test from Other Genomic Assays
Which Patients are Eligible for Breast Cancer Index® Testing and When To Order the Test
2:01
Which Patients are Eligible for Breast Cancer Index® Testing and When To Order the Test
How Physicians and Advanced Practitioners Partner to Provide Personalized Care
3:26
How Physicians and Advanced Practitioners Partner to Provide Personalized Care
BCI Test Empowers Physicians and Advanced Practitioners to Make Shared Decisions with Their Patients
2:16
BCI Test Empowers Physicians and Advanced Practitioners to Make Shared Decisions with Their Patients
Breast Cancer Index® Testing Enables Informed Shared Decision Making Between Patients and Providers
2:01
Breast Cancer Index® Testing Enables Informed Shared Decision Making Between Patients and Providers
Help Increase Patient Adherence to Extended Endocrine Therapy Recommendations
5:46
Help Increase Patient Adherence to Extended Endocrine Therapy Recommendations
Clinically Low-Risk Patients May Be Misclassified and Require Longer Treatment
4:31
Clinically Low-Risk Patients May Be Misclassified and Require Longer Treatment
De-Escalate Clinically High-Risk Patients Who Are Unlikely to Benefit from EET
5:01
De-Escalate Clinically High-Risk Patients Who Are Unlikely to Benefit from EET
Not All Women Who Are Clinically High-Risk Benefit from Extended Endocrine Therapy
5:41
Not All Women Who Are Clinically High-Risk Benefit from Extended Endocrine Therapy
Are You Making Optimal Extended Endocrine Decisions with Your Patients?
1:56
Are You Making Optimal Extended Endocrine Decisions with Your Patients?
The Only Guideline Recognized Test to Predict Extended Endocrine Therapy Benefit
8:23
The Only Guideline Recognized Test to Predict Extended Endocrine Therapy Benefit
The Breast Cancer Index® Test: Easy to Interpret Predictive and Prognostic Results
5:31
The Breast Cancer Index® Test: Easy to Interpret Predictive and Prognostic Results
Which women with HR+, early-stage breast cancer benefit from extended endocrine therapy?
3:46
Which women with HR+, early-stage breast cancer benefit from extended endocrine therapy?
Partnering to Provide Personalized Care: Patient Selection for Extended Endocrine Therapy
1:00:46
Partnering to Provide Personalized Care: Patient Selection for Extended Endocrine Therapy
BCI Case Study: Help Avoid Over-Treatment
6:22
BCI Case Study: Help Avoid Over-Treatment
BCI: Guideline-Recognized and Validated to Help Guide Extended Endocrine Decisions
2:53
BCI: Guideline-Recognized and Validated to Help Guide Extended Endocrine Decisions
BCI Case Study: Help Avoid Under-Treatment with the Breast Cancer Index Test
1:43
BCI Case Study: Help Avoid Under-Treatment with the Breast Cancer Index Test
Compromising Treatment Length May Mean Compromising Benefit: 7.5 vs 10 years
1:00
Compromising Treatment Length May Mean Compromising Benefit: 7.5 vs 10 years
De-Escalating Clinically High Risk Patients Who Are Not Likely to Benefit from EET
1:36
De-Escalating Clinically High Risk Patients Who Are Not Likely to Benefit from EET
Determining Benefit of Ovarian Function Suppression: SOFT Trial
7:12
Determining Benefit of Ovarian Function Suppression: SOFT Trial
Extended Endocrine Therapy: Who Will Benefit?
6:35
Extended Endocrine Therapy: Who Will Benefit?
Managing patients with substantial risk of recurrence who are not likely to benefit from EET
1:19
Managing patients with substantial risk of recurrence who are not likely to benefit from EET
Physicians May Change Treatment Recommendations Following BCI...
1:31
Physicians May Change Treatment Recommendations Following BCI...
Utilizing the Appropriate Tool for Extended Endocrine Therapy Decision-Making: BCI vs Oncotype Dx
1:39
Utilizing the Appropriate Tool for Extended Endocrine Therapy Decision-Making: BCI vs Oncotype Dx
BCI: An Established Tool for Use in N1 Patients
2:27
BCI: An Established Tool for Use in N1 Patients